| 1 |
陈自谦，杨利，杨熙章，等.肝癌介入治疗现状与进展[J].介入放射学杂志，2008，17(3): 223-227.
|
| 2 |
沈俊杰，陈自谦，王曙东，等.中药组方作为血管栓塞剂的实验研究[J].医学研究生学报，2005,18(10): 893-895.
|
| 3 |
王子妤，张东生.纳米药物的研究进展[J].东南大学学报(医学版)，2004,23(2): 131-135.
|
| 4 |
Kamada K, Kitamoto M, Aikata H, et al. Combination of transcatheter arterial chemo-embolization using cisplatin lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma[J].Am J Surg,2002,184(3): 284-290.
|
| 5 |
Choi D, Lim HK, Kim MJ, et al. Recurrent hepatocellular carcinoma: percutaneous radiofrequency ablation after hepatectomy[J].Radiology,2004,230(1): 135-141.
|
| 6 |
Dong B, Liang P, Yu X, et al. Percutaneous US-guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients[J].AJR Am J Roentgenol,2003,180(6): 1574-1555.
|
| 7 |
周信达，汤钊猷，杨秉辉，等．1000例小肝癌手术切除经验[J]．中国实用外科杂志，2001，21(21): 41-44．
|
| 8 |
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699.
|
| 9 |
Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list[J]. Liver Transpl, 2002,8(10): 873-883.
|
| 10 |
Yang W, Guo C, Liu QG, et al. Experimental study of specific immunotherapy induced by H22 autologous tumor as whole tumor cell vaccine[J]. Biomed Pharmacother, 2009,63(6): 404-408.
|
| 11 |
Kuang M, Peng BG, Lu MD, et al. Phase Ⅱ randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma[J]. Clin Cancer Res, 2004,10(5): 1574-1579.
|
| 12 |
Peng B, Liang L, Chen Z, et al. Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma[J].Hepatogastroenterology,2006,53(69): 409-414.
|
| 13 |
Butterfield LH, Ribas A, Meng WS, et a1. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer[J]. Clin Cancer Res, 2003,9(16 Pt1): 5902-5908.
|
| 14 |
Butteffield LH, Ribas A, Dissette VB, et a1. A phase Ⅰ/Ⅱ trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides[J]. Clin Cancer Res, 2006,12(9): 2817-2825.
|
| 15 |
Bertelli R, Neri F, Tsivian M, et al. Endolymphatic immunotherapy in inoperable hepatocellular carcinoma[J]. Transplant Proc, 2008, 40(6): 1913-1915.
|
| 16 |
Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet, 2000,356(9232): 802-807.
|
| 17 |
Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection[J]. J Clin Oncol, 2007,25(18): 2586-2593.
|
| 18 |
Cheng SQ, Wu MC, Chen H, et al. Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma[J]. Zhonghua Zhong Liu Za Zhi, 2004,26(5): 305-307.
|
| 19 |
Shuqun C, Mengchao W, Han C, et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection[J]. Hepatogastroenterology, 2006,53(68): 249-252.
|
| 20 |
Sangro B, Mazzolini G, Ruiz J, et a1. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors[J]. J Clin Oncol, 2004,22(8): 1389-1397.
|
| 21 |
Tomova R, Antonov K, Ivanova A, et al. Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report[J]. Anticancer Res, 2009,29(12): 5241-5244.
|
| 22 |
Palmieri G, Montella L, Milo M, et al. Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma[J]. Am J Clin Oncol, 2002,25(3): 224-226.
|
| 23 |
Lo CM, Liu CL, Chan SC, et a1. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma[J]. Ann Surg, 2007,245(6): 831-842.
|
| 24 |
Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis[J]. Hepatology, 2006,44(6): 1543-1554.
|
| 25 |
Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver[J]. Semin Radiat Oncol, 2001,11(3): 240-246.
|
| 26 |
Cheng JC, Chou CH, Kuo ML, et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt /NFkappaB signal transduction pathway[J]. Oncogene, 2006,25(53): 7009-7018.
|
| 27 |
Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulat ory gene therapy with interleukin 12 and 4-1BB ligand: long-t erm remission of liver metastases in a mouse model [J]. J Natl Cancet Inst, 2008,92(11): 931-936.
|
| 28 |
Krarner MG, Barajas M, Razquin N, et al. Invitro and in vivo comparative study of chimeric liver-specific promoters[J]. Mol Ther, 2003,7(3): 375-385.
|
| 29 |
Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogenactivated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma[J]. Hepatology,1998,27(4): 951-958.
|
| 30 |
Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential[J]. FASEB J, 2004,18(10): 1123-1125.
|
| 31 |
Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinasesVEGFR/PDGFR in tumor vasculature[J]. Methods Enzymol, 2006,407: 597-612.
|
| 32 |
Ogasawara S, Yano H, Momosaki S, et al. Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues[J]. Oncol Rep, 2005,13(6): 1043-1048.
|
| 33 |
Dhar DK, Oon T, Yamanoi A, et al. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma[J].Cancer, 2002,95(10): 2188-2195.
|